We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$356M
AUM Growth
+$69.2M
Cap. Flow
+$66.4M
Cap. Flow %
18.67%
Top 10 Hldgs %
43.39%
Holding
101
New
33
Increased
27
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$23M
2
CRNX
Crinetics Pharmaceuticals
CRNX
+$9.27M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$8.98M
4
KRYS icon
Krystal Biotech
KRYS
+$7.02M
5
ACLX
Arcellx
ACLX
+$5.99M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.3M
2
BIIB icon
Biogen
BIIB
+$11.4M
3
VTYX
Ventyx Biosciences
VTYX
+$3.3M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$2.97M
5
KYNB
Kyntra Bio
KYNB
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 81.22%
2 Miscellaneous 18.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE
1
DELISTED
Apogee Therapeutics
APGE
$22.3M 6.26%
+1,045,110
New +$23M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$42.4B
$20.4M 5.74%
2,000,000
+400,000
+25% +$3.72M
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
$16.8M 4.74%
1,129,376
+79,258
+8% +$1.05M
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$15M 4.21%
685,061
+135,061
+25% +$3.38M
ACLX
5
DELISTED
Arcellx
ACLX
$14.4M 4.04%
400,000
+173,725
+77% +$5.99M
CRNX
6
DELISTED
Crinetics Pharmaceuticals
CRNX
$13.4M 3.76%
+450,000
New +$9.27M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.5B
$12.4M 3.49%
85,000
-7,500
-8% -$1.41M
ESTA icon
8
Establishment Labs
ESTA
$2.21B
$11.7M 3.3%
239,108
+27,500
+13% +$1.64M
IMVT icon
9
Immunovant
IMVT
$8.11B
$11.5M 3.24%
300,000
+40,000
+15% +$904K
TEVA icon
10
CALL
Teva Pharmaceuticals
TEVA
$42.4B
$11.2M 3.16%
+1,100,000
New +$10.2M
XENE icon
11
Xenon Pharmaceuticals
XENE
$5.79B
$10.3M 2.89%
300,438
+240,062
+398% +$8.98M
KURA icon
12
Kura Oncology
KURA
$1.18B
$7.81M 2.2%
856,535
-53,782
-6% -$546K
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$7.46M 2.1%
1,000,300
+349,425
+54% +$2.98M
ARKG icon
14
PUT
ARK Genomic Revolution ETF
ARKG
$2B
$6.96M 1.96%
+250,000
New +$8.17M
ESTA icon
15
CALL
Establishment Labs
ESTA
$2.21B
$6.87M 1.93%
+140,000
New +$8.37M
CYTK icon
16
Cytokinetics
CYTK
$10.1B
$6.79M 1.91%
230,366
+105,218
+84% +$3.5M
KRYS icon
17
Krystal Biotech
KRYS
$10.6B
$6.67M 1.88%
+57,500
New +$7.02M
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$6.59M 1.85%
1,018,091
+117,368
+13% +$803K
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.19M 1.74%
270,000
+68,113
+34% +$3.57M
VRNA
20
DELISTED
Verona Pharma
VRNA
$6M 1.69%
368,329
-79,338
-18% -$1.53M
INZY
21
DELISTED
Inozyme Pharma
INZY
$5.8M 1.63%
1,379,852
+628,056
+84% +$3.19M
ALKS icon
22
CALL
Alkermes
ALKS
$7.73B
$5.6M 1.58%
+200,000
New +$5.86M
APLS
23
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$4.95M 1.39%
+130,000
New +$5.71M
IMVT icon
24
PUT
Immunovant
IMVT
$8.11B
$4.92M 1.38%
+128,100
New +$2.9M
AUTL
25
Autolus Therapeutics
AUTL
$596M
$4.64M 1.31%
1,992,466
+403,449
+25% +$1.15M
1
2 3 4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Affinity Asset Advisors held 101 positions worth $356M, up 24% from $286M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $66.4M of net new capital in Q3 2023, opening 33 new positions and adding to 27 existing holdings. Its largest new stake was Apogee Therapeutics: 1,045,110 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 83% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $2.42M trimmed.

  • Affinity Asset Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,045,110 shares worth $22.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q3 2023, an estimated $8.98M increase.
  • Affinity Asset Advisors's biggest Q3 2023 reduction was SpringWorks Therapeutics, cutting an estimated $2.42M.
  • Affinity Asset Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $12.3M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $356M portfolio in Q3 2023.
  • Affinity Asset Advisors opened 33 new positions and closed 20 in Q3 2023.
  • Affinity Asset Advisors's portfolio value rose 24% quarter-over-quarter to $356M.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.